Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

• Published in: Circulation (New York, N.Y.) Vol. 141; no. 8; pp. 616 - 623
• Main Authors: Marston, Nicholas A., Kamanu, Frederick K., Nordio, Francesco, Gurmu, Yared, Roselli, Carolina, Sever, Peter S., Pedersen, Terje R., Keech, Anthony C., Wang, Huei, Lira Pineda, Armando, Giugliano, Robert P., Lubitz, Steven A., Ellinor, Patrick T., Sabatine, Marc S., Ruff, Christian T.
• Format: Journal Article
• Language: English
• Published: United States by the American College of Cardiology Foundation and the American Heart Association, Inc 25.02.2020
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - therapeutic use; Anticholesteremic Agents - therapeutic use; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - etiology; Cholesterol, LDL - blood; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; PCSK9 Inhibitors; Placebo Effect; Polymorphism, Single Nucleotide; Proportional Hazards Models; Proprotein Convertase 9 - genetics; Proprotein Convertase 9 - metabolism; Risk Factors; cardiovascular disease; risk factors; genetics; PCSK9 protein, human; evolocumab

BACKGROUND:The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established. METHODS:We studied 14 298 patients with atheroscler...